Table 1.

Study Population and Annual Prevalence of PAP Syndrome in the US^a

Study year	Total patientsb	Total PAP patientsc	Total PAP prevalence per million patientsd
2008	15,519,985	105	6.77
2009	15,686,604	127	8.10
2010	16,070,700	103	6.41
2011	15,764,422	109	6.91
2012	16,515,902	102	6.18
Mean	15,911,523	109	6.87
Study year	Total female patientsb	Female PAP patientsc	PAP prevalence per million female patientse
2008	7,953,672	51	6.41
2009	8,038,763	67	8.33
2010	8,233,635	57	6.92
2011	8,069,748	67	8.30
2012	8,427,886	59	7.00
Mean	8,144,741	60	7.39
Study year	Total male patientsb	Male PAP patientsc	PAP prevalence per million male patientsf
2008	7,566,313	54	7.14
2009	7,647,841	60	7.85
2010	7,837,065	46	5.87
2011	7,694,674	42	5.46
2012	8,088,016	43	5.32
Mean	7,766,782	49	6.31

Definition of abbreviations: PAP pulmonary alveolar proteinosis

^aPatients are individuals represented by de-identified data in the OptumInsight database during the study period meeting the inclusion and exclusion criteria as defined in the methods

^bIncludes all (or female/male patients as indicated) with complete annual claims data for at least two consecutive years

^cIncludes all (or female/male patients as indicated) patients with at least one claim associated with an ICD-9516.0 code in the respective calendar year

^dCalculated as the number of PAP patients in each year divided by the total number of patients included in that year

^eCalculated as the number of female PAP patients in each year divided by the number of female patients included in that year

^fCalculated as the number of male PAP patients in each year divided by the number of male patients included in that year